Homegrown mRNA players BioNTech and CureVac have signed on to supply Germany with vaccines against future health emergencies for years to come. Germany will pay …
A now-former Pfizer employee is playing nice after the drugmaker sued her in November alleging the 15-year veteran uploaded more than 12,000 sensitive files—including documents …
The COVID-19 vaccine produced by Pfizer and BioNTech, Comirnaty, provides less protection against the omicron variant than it did against wild-type COVID and other variants, …
As the world assesses the threat posed by the COVID-19 omicron variant, two top companies producing pandemic drugs and vaccines have warned that their current …
AstraZeneca’s chief executive Pascal Soriot is challenging the notion that his company’s vaccine is inferior to the mRNA vaccines from Moderna and Pfizer. In fact, …
The COVID-19 pandemic is creating a $100 billion pharma goliath. Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s …
Like its partner on its COVID-19 vaccine, BioNTech keeps upping its estimate for 2021 vaccine revenue. Last week, Pfizer jacked up its annual guidance on …
When posed with the decades-old question of how drug price reform would affect their operations in the U.S., pharma execs have a ready-made response: Reducing …
The COVID-19 pandemic helped put mRNA vaccines on the map. Now, thanks to the shots’ quick uptake in rich countries, mRNA specialist BioNTech appears poised …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.